RTTNews | Jun 28, 2021 10:05AM EDT

10:05 Monday, June 28, 2021 (RTTNews.com) - Shares of Editas Medicine Inc. (EDIT) are currently trading at $46.10, up $4.22 or 10.08%, with trading volume soaring over 2.47 million versus an average volume of 1.26 million shares. The stock has been trading between $27.01 and $99.95 for the past one year.

On June 23, the company announced that centers are now enrolling the first of two planned pediatric cohorts in the Phase 1/2 BRILLIANCE clinical trial of EDIT-101 following the Independent Data Monitoring Committee or IDMC endorsement to proceed.

The IDMC endorsement is based on an analysis of safety data from the adult low-dose and adult mid-dose cohorts. The company also announced the completion of dosing of the adult mid-dose cohort.

The company further noted that both the pediatric mid-dose cohort and the adult high-dose cohort would run concurrently. For both cohorts, first dosing is expected this summer and completion is expected in the first half of 2022.

Read the original article on RTTNews ( https://www.rttnews.com/3205453/editas-medicine-gains-10.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved